41 results about "Docetaxel" patented technology

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

The application discloses a micelle containing a taxane drug, a preparation method and application thereof. The application provides a micelle containing substance A, which comprises the following components in parts by weight: 1 part of substance A and 5-25 parts of polyethylene glycol derivatized phospholipid; the substance A is docetaxel and / or cabazitaxel; and the polyethylene glycol derivatized phospholipid comprises a polyethylene glycol part and a phospholipid part, wherein the phospholipid part is di(C 12 ‑C 24 phosphatidylethanolamine. The micelle containing the taxane drug can contain a therapeutically effective amount of the taxane drug, the drug loading capacity is as high as 6.25%-9.09%, the stability is good, and the problems in clinical application can be effectively solved.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.

The present invention is directed to polymer-drug conjugates and / or compositions and / or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and / or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and / or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.

The invention discloses a docetaxel-loaded retinoic acid derivative polymer micelle and a preparation method thereof, and belongs to the technical field of biological medicines. The polymer micelle is prepared from docetaxel and a retinoic acid derivative polymer mPR. The preparation method comprises the following steps: mixing and dispersing the polymer mPR and docetaxel into a drug film, and hydrating with a proper medium to prepare the polymer micelle. The docetaxel polymer micelle disclosed by the invention is high in encapsulation efficiency, high in drug loading capacity, high in stability and relatively good in curative effect and safety.

The invention discloses an application of docetaxel in preparation of drugs for resisting toxoplasmosis, and belongs to the technical field of medicines. Through a series of experimental studies, it is found that docetaxel can significantly delay the onset time of mice infected with toxoplasma gondii virulent strains and effectively reduce the death rate of mice infected with toxoplasma gondii attenuated strains. Docetaxel shows a relatively strong inhibition effect in the aspect of treating related diseases caused by a virulent strain or a low virulent strain of toxoplasma gondii, and can effectively slow down the infection process and prolong the life cycle of a host. In combination with in-vitro cell experiment and in-vivo animal experiment results, the taxane drug has a good treatment prospect, can be used as a development basis of a novel toxoplasmosis-resistant drug, and promotes the realization of a novel treatment scheme.

This invention relates to the field of biomedical materials and pharmaceutical formulations, disclosing an FH peptide-polydopamine-coated graphene oxide drug delivery system and its preparation and application. The system includes an RGD peptide-modified graphene oxide carrier, a polydopamine shell, and a drug loaded within the system. The polydopamine shell is surface-modified with an FH peptide. The drugs include docetaxel and losartan, with docetaxel loaded on the RGD peptide-modified graphene oxide carrier and losartan loaded in the FH peptide-modified polydopamine shell. This FH peptide-polydopamine-coated graphene oxide drug delivery system, through surface modification of graphene oxide with an RGD peptide and coating with a polydopamine shell, effectively shields against the potential cytotoxicity and blood incompatibility risks of unmodified graphene oxide. Compared to unmodified graphene oxide carriers, this system shows significantly improved compatibility at both normal and tumor cell levels, maintaining extremely high cell viability across a wide concentration range.

This disclosure is directed to a pharmaceutical composition comprising sodium bicarbonate and a polymer-drug nanoaggregate having a polymer and a taxane. The polymer is water soluble and comprises at least one first terminal group modified with a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. The taxane can include paclitaxel, docetaxel, cabazitaxel, larotaxel, milataxel, ortataxel, tesetaxel, derivatives therefrom or a combination thereof, which are water insoluble or poorly water soluble. Such polymer-drug nanoaggregates can improve drug solubility, stability, in vivo availability and efficacy, and reduce side effects such as renal toxicity. This invention is also directed to a process for producing the pharmaceutical composition comprising the polymer-drug nanoaggregate. This invention is further directed to a method for treating a disease including cancer using the pharmaceutical composition disclosed herein.

The invention belongs to the technical field of biology, and particularly relates to a pharmaceutical composition for inducing gonad exhaustion of paralichthys olivaceus and application of the pharmaceutical composition. The pharmaceutical composition comprises docetaxel and cis-platinum, the mass ratio of docetaxel to cis-platinum is 1: 1, and the total concentration of docetaxel and cis-platinum is 100-200 mu g / mL. By optimizing the medicine proportion and the administration scheme, the problems of low survival rate and large injury of fish bodies in the existing gonad exhaustion method are solved, and efficient and stable preparation of the paralichthys olivaceus germline stem cell transplantation receptor can be realized. By controlling the ratio of docetaxel to cis-platinum, the administration concentration, the injection frequency, the action period and the like, the invention aims to solve the problems of insufficient exhaustion effect, low fish survival rate or serious gonad injury and the like in the existing receptor preparation, and provides reliable technical support for establishing a stable and efficient paralichthys olivaceus germline stem cell transplantation receptor system.

The invention relates to a nano compound loaded with EZH2siRNA and docetaxel, which is characterized in that a zeolite imidazole skeleton (ZIF-8) is used as a carrier for siRNA delivery, then siRNA (ZIF)-8NPs is coated by using double-layer lipid, and meanwhile, the docetaxel (DTXL) is loaded in the double-layer lipid. The nano-composite loaded with EZH2siRNA and docetaxel has the beneficial effects that 1, the nano-composite loaded with EZH2siRNA and docetaxel is small in side effect as a drug, and the drug distribution at the bone metastatic focus of prostate cancer is relatively good; 2, the ZIF-8 has strong positive charges and can effectively adsorb siRNA with negative charges; 3, the nano drug loading system with a core-shell structure can more efficiently co-deliver siRNA and docetaxel, the core structure ZIF-8 can effectively load siRNA, and a shell lipid bilayer can effectively deliver a chemotherapeutic drug DTXL; and 4, the nano-composite loaded with the EZH2siRNA and the docetaxel is used as a medicine, so that the targeting property is high, and alendphosphate groups in middle and outer layer lipid DOPE-PEG-Alendronate can be effectively distributed to bone metastasis lesion in a targeting manner.

Disclosed herein is a method for predicting whether a subject with cancer will exhibit a beneficial response to arginine deficiency therapy. The method includes the step of determining the plasma concentration of arginine in the subject, followed by administering arginine deficiency therapy to the subject alone or in combination with an anticancer agent, based on the determined plasma concentration of arginine. According to some embodiments of this disclosure, the anticancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and combinations thereof.

The present invention provides a pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising a mixed extract of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii Maximowicz; and an anticancer agent, and a method for preventing or treating cancer using the pharmaceutical composition.

The present disclosure relates to methods of treating cancer in a subject by administering to the subject effective amounts of an anti-CCR8 antibody, a chemotherapeutic agent (e.g., cisplatin, gemcitabine, docetaxel), and a PD1 inhibitor or a PD-L1 inhibitor. In some embodiments, the chemotherapeutic agent is administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody. In some embodiments, the chemotherapeutic agents are co-administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody.

The invention discloses a preparation process of docetaxel albumin nanoparticles, and belongs to the technical field of biological medicine preparation, the key point of the technical scheme is that the preparation process of the docetaxel albumin nanoparticles comprises the following preparation steps: S1, dissolving docetaxel in an organic solvent; s2, controlling the pH value of the aqueous solution containing arginine in a range of 4-6; s3, adding albumin into the arginine aqueous solution obtained in the step S2, and performing low-temperature shearing to obtain an albumin arginine aqueous solution; s4, reacting the albumin arginine aqueous solution obtained in the step S3 with the mixture obtained in the step S1 to obtain a reaction solution; and S5, carrying out high-pressure homogenization on the reaction liquid to obtain the docetaxel albumin nanoparticles. The docetaxel albumin nanoparticles obtained by taking arginine as a developing solvent of albumin are completely stable within 5 hours, the stability exceeds 24 hours when the docetaxel albumin nanoparticles are stored at 4 DEG C, and the phenomenon of precipitation or precipitation does not occur.

Use of a docetaxel-albumin composition in the preparation of a drug for treating gastric cancer or gastroesophageal junction cancer, a method for treating gastric cancer or gastroesophageal junction cancer using the docetaxel-albumin composition, and a drug or kit comprising the docetaxel-albumin composition for treating gastric cancer or gastroesophageal junction cancer. The docetaxel-albumin composition can treat gastric cancer or gastroesophageal junction cancer.

The application discloses a kind of photodynamic balloon catheter systems, comprising: tube body, with opposite proximal end and distal end;Balloon, the balloon is fixed in the distal end portion of the tube body;Optical fiber assembly is inserted in the tube body, and with the light-emitting site extending to adjacent the balloon;The surface of the balloon is loaded with auxiliary material and photosensitizer in the form of coating;The photosensitizer can activate collagen and elastin under the wavelength of light 400-460nm to make them crosslink;The auxiliary material includes active drug and sustained-release material wrapped the active drug, the active drug is at least one of paclitaxel, rapamycin, zotarolimus, tacrolimus, everolimus, temsirolimus, zanolimus, biolimus, docetaxel, protein-bound paclitaxel and protein-bound dexamethasone;By the photodynamic balloon catheter system of the application can improve the utilization rate of active drug in intravascular administration.

The invention discloses a purification method of a docetaxel intermediate. The purification method comprises the following steps: dissolving the docetaxel intermediate with an organic solvent; carrying out hot filtration on the dissolved solution to obtain filtrate; cooling the filtrate, dropwise adding alkane, cooling and crystallizing; and centrifuging, washing and drying to obtain the required docetaxel intermediate. The purification method of the docetaxel intermediate provided by the invention is simple to operate and low in cost, the purity of the docetaxel intermediate can reach 99% or above, the quality is high, the stability is good, the contents of trisubstituted impurities and oxidized impurities are both less than 0.1%, the yield is as high as 95% or above, and the quality of a docetaxel finished product is indirectly improved by improving the quality of the docetaxel intermediate; common reagents are adopted, are cheap and easy to obtain, are beneficial to environmental protection and are suitable for industrial production.

The present application relates to a kind of isoquinoline alkaloid derivatives for reversing tumor multidrug resistance by inhibiting autophagy and preparation method and application.The derivative can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer and esophageal cancer, the derivative can inhibit the autophagy flow of tumor cells, it is combined with vincristine, mitoxantrone, colchicine, docetaxel and various chemotherapeutic drugs, can efficiently reverse tumor multidrug resistance in vivo and in vitro, this kind of derivative has excellent oral bioavailability and lower toxic side effects, provides a kind of alternative strategy for autophagy inhibitor as antitumor chemosensitizer, can be used as lead compound for the research and development of new drug-resistant tumor reversing agent.

This invention discloses the application of UFSP2 in the auxiliary diagnosis or treatment of prostate cancer, belonging to the field of biomedical technology. Experimental verification revealed that UFSP2 can serve as a diagnostic biomarker for prostate cancer and also possesses the potential to predict biochemical recurrence. Furthermore, this invention found that inhibiting UFSP2 expression significantly enhances the proliferation, migration, and colony formation capabilities of cells; upregulating UFSP2 expression significantly inhibits these capabilities, indicating that UFSP2 can serve as a therapeutic target for prostate cancer. Further, upregulating UFSP2 expression can also enhance the sensitivity of cancer cells to the chemotherapy drug docetaxel, suggesting that enhancing UFSP2 helps improve the therapeutic effect of chemotherapy drugs on prostate cancer. In summary, this invention provides a new biomarker for the diagnosis of prostate cancer and offers new targets and approaches for its treatment.

The invention discloses application of parabacteroides dieldrii in preparation of a medicine for treating prostatic cancer, and belongs to the field of biological medicine. It is found for the first time that the abundance of parabacteroides dieldrii in intestinal flora of a prostate cancer patient is remarkably reduced, and the parabacteroides dieldrii is selected as potential probiotics for inhibiting growth of prostate cancer tumors. The result of a parabacteroides dieldrii single bacterium colonization experiment shows that the parabacteroides dieldrii and the metabolite gamma-linolenic acid (GLA) thereof can efficiently inhibit the growth of the prostatic cancer tumor, can also improve the condition that the treatment effect of docetaxel on the prostatic cancer is poor due to abuse of clinical antibiotics, and can be prepared into the medicine for treating or assisting in treating the prostatic cancer. The invention provides a new treatment strategy and medicine for the treatment of the prostatic cancer, and also provides a brand new medicine development path and a clinical application scheme for the micro-ecological treatment of the prostatic cancer.

Provided herein are methods of treating a cancer in a subject, and methods of improving responsiveness of a subject to a cancer therapy. Also provided herein is tigilanol tiglate and pharmaceutical compositions thereof for use in such methods, and uses of tigilanol tiglate and pharmaceutical compositions thereof for treating cancer and improving responsiveness to a subsequent cancer therapy, such as immune checkpoint inhibitors, gemcitabine, docetaxel, or temololomide.

Disclosed herein are methods, including methods for determining a response to treatment comprising ADT and a taxane compound, for example docetaxel, that a subject with metastatic prostate cancer is expected to have based on at least the expression level a plurality of targets in the sample from the subject. In some embodiments, the methods include administering or having administered to the subject with metastatic prostate cancer in a treatment selected from: a treatment comprising ADT and a taxane compound, for example docetaxel; or a treatment comprising ADT and not comprising a taxane compound, for example docetaxel, wherein the treatment is selected based on the expected response to treatment comprising ADT and the taxane compound, for example docetaxel. Also disclosed are kits and reagents used for performing the methods.

The present application provides a docetaxel albumin nano-composition and a preparation method thereof. Specifically, the present application provides a docetaxel albumin nano-preparation, which comprises: 1-30 parts by weight of docetaxel, 5-50 parts by weight of albumin, 5-85 parts by weight of a stabilizer; and optionally a pharmaceutical lyophilized excipient.

To provide an infusible and stable pharmaceutical composition comprising docetaxel or a pharmaceutically acceptable salt thereof.SOLUTION: A pharmaceutical formulation of docetaxel or a pharmaceutically acceptable salt thereof comprising two compositions that are mixed prior to being infused or administered to a patient, the formulation comprising: (a) a first liquid composition comprising docetaxel or a pharmaceutically acceptable salt thereof and ethanol; and (b) a second aqueous composition comprising human serum albumin and a parenterally acceptable vehicle, wherein the pharmaceutical formulation does not contain Polysorbate 80.SELECTED DRAWING: None

The invention provides a maleimide derivative with rapid activation capability and a liposome and application thereof. The derivative provided by the invention has a rapid activation connecting bond, and is adaptive to drugs containing hydroxyl or amino groups, such as R848 (R848), camptothecin (CPT), docetaxel (DTX), paclitaxel (PTX) and the like. The active drug-loading liposome is composed of the derivative, phospholipid, cholesterol, PEGylated phospholipid and a water-soluble sulfydryl substance. The derivative disclosed by the invention is high in activation rate in plasma, in-vitro experiments prove that the corresponding liposome can effectively kill cancer cells, has an excellent in-vitro anti-tumor effect, and can be used for preparing medicines for preventing or treating tumors.

The invention provides a polypeptide conjugate and application thereof, and particularly relates to a paclitaxel or docetaxel polypeptide conjugate and application thereof. The polypeptide coupling drug provided by the invention is selectively released in a tumor microenvironment, the problem that clinical application is limited due to the fact that paclitaxel or docetaxel drugs do not have targeting performance and have strong side effects in the prior art can be solved, a larger dosage can be clinically used for treating cancers, and the overall treatment effect is improved.

This invention relates to a lalotasyl-derived taxane compound, specifically a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Wherein R 1 Selected from hydrogen, C 1‑6 Alkyl, cycloalkyl, aryl, or benzyl groups. This invention also provides methods for preparing the compounds and their use in the preparation of medicaments for the prevention and / or treatment of tumors. In vitro antitumor activity tests show that these compounds have significant inhibitory activity against various human cancer cell lines, including non-small cell lung cancer cell line A549, breast cancer cell line MCF-7, triple-negative breast cancer cell line MDA-MB-231, glioblastoma cell line U251, paclitaxel-resistant non-small cell lung cancer cell line A549Tax, and doxorubicin-resistant breast cancer cell line MCF-7 / ADR. Some of these compounds showed 136-462 times greater activity against A549 cells than lalostatin. The compounds of this invention possess excellent antitumor activity and are expected to be used in the preparation of medicaments for the treatment of tumors such as lung cancer, breast cancer, or glioma.

The application provides a coumarin derivative and a preparation method thereof, which comprises the following steps: dissolving coumarin, N,N-diisopropylethylamine and O-benzotriazole-tetramethyl urea hexafluorophosphate in N,N-dimethylformamide to react, then adding amino-functionalized polyethylene glycol, after reaction, separating by column chromatography to obtain an intermediate product; mixing the intermediate product with DL-pyroglutamic acid, adding N,N-diisopropylethylamine and O-benzotriazole-tetramethyl urea hexafluorophosphate to react, and separating by column chromatography to obtain the coumarin derivative. The application also provides an application for preparing an anti-prostate cancer drug or an endothelin receptor A antagonistic drug. The coumarin derivative of the application can significantly inhibit the proliferation of prostate cancer cells LNCaP, can significantly inhibit the expression of endothelin receptor A in tumor tissues under a dosing amount of 20 mg / kg, and can obviously reduce the expression level of prostate specific antigen in serum when combined with docetaxel, so as to play an anti-tumor proliferation role.